Menu
Copay Program Copay Program

FINANCIAL ASSISTANCE FOR PATIENTS WITH COMMERCIAL INSURANCE

With the Copay Coupon, eligible patients can pay as little as $0 for AURYXIA—with savings up to $500 per 30-day fill

COPAY SAVINGS ELIGIBILITY

In order to qualify for the AURYXIA Copay Coupon, patients must:

  • Have commercial insurance only (commercial health insurance is any type of health benefit not affiliated with a federal or state government program)
  • Not be registered for Medicare, Medicaid, Veterans Affairs, or similar federal or state programs

COPAY MAIL-IN REBATE OPTION

Some pharmacies may require patients to mail in their Copay Coupon.
To redeem their copay, patients must submit:

  • A copy of the Copay Coupon OR the ID number and Group number located on the coupon
  • The original purchase receipt with prescription number, pill quantity, and name of pharmacy where filled
  • Patient's name, full address, phone number, and date of birth

Please send all necessary documents to:

AURYXIA Claims Processing Dept

PO Box 7017

Bedminster, NJ 07921-7017

Allow up to 6 weeks for processing. Same Copay Coupon rules and regulations apply.

TIP: Be sure your patient keeps a photocopy of all submitted materials for their records.

INDICATIONS

AURYXIA® (ferric citrate) is indicated for:

  • The control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis
  • The treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis

WARNINGS AND PRECAUTIONS

  • Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy. Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy
  • Risk of Overdosage in Children Due to Accidental Ingestion: Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Advise patients of the risks to children and to keep AURYXIA out of the reach of children

ADVERSE REACTIONS

The most common adverse reactions reported with AURYXIA in clinical trials were:

  • Hyperphosphatemia in CKD on Dialysis: Diarrhea (21%), discolored feces (19%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%)
  • Iron Deficiency Anemia in CKD Not on Dialysis: Discolored feces (22%), diarrhea (21%), constipation (18%), nausea (10%), abdominal pain (5%) and hyperkalemia (5%)

SPECIFIC POPULATIONS

  • Pregnancy and Lactation: There are no available data on AURYXIA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation. Data from rat studies have shown the transfer of iron into milk, hence, there is a possibility of infant exposure when AURYXIA is administered to a nursing woman

To report suspected adverse reactions, contact Akebia Therapeutics, Inc. at 1-844-445-3799

Please see full Prescribing Information